Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors-Reference-Cited by-同舟云学术

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Published:2022-10-18 Issue:1 Volume:16 Page:73-84
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Centanni Maddalena¹^ORCID,Thijs Abel²,Desar Ingrid³,Karlsson Mats O.¹,Friberg Lena E.¹^ORCID

Affiliation:

1. Department of Pharmacy Uppsala University Uppsala Sweden

2. Department of Internal Medicine, Amsterdam UMC Location VU University Amsterdam The Netherlands

3. Department of Medical Oncology Radboud University Medical Center Nijmegen The Netherlands

Funder

Cancerfonden

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13423

Reference49 articles.

1. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

2. MRC Protein Phosphorylation Unit. List of clinically approved kinase inhibitors.2021. Accessed April 22 2022.https://www.ppu.mrc.ac.uk/list‐clinically‐approved‐kinase‐inhibitors

3. Individualized dosing with axitinib: rationale and practical guidance

4. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring

5. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

2. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children;Cancer Chemotherapy and Pharmacology;2024-05-23

3. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children;2023-12-08